We demonstrate the therapeutic potential of tumor suppressor(e.g., PTEN and p53)-coded mRNA in inhibiting tumor growth, enhancingantitumor immunity, and improving other therapies such as immune checkpointblockade.−, , , , ,  We hypothesize that using mRNA and siRNA to concurrently restoretumor suppressors (e.g., PTEN) and inhibit tumorigenic drivers (e.g.,AR) could represent a unique strategy for correcting both aspectsof the cellular signaling imbalance for the highly effective treatmentof PCa. Here, AR is linked to neoplasm.